Skip to content

Pulmonary Function Using Non-invasive Forced Oscillometry

Pulmonary Function Using Non-invasive Forced Oscillometry Respiratory Testing: A Prospective Observational Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03346343
Acronym
PUFFOR
Enrollment
600
Registered
2017-11-17
Start date
2017-12-06
Completion date
2027-05-01
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchopulmonary Dysplasia, Infant, Newborn, Diseases, Infant, Premature, Diseases, Meconium Aspiration Syndrome, Respiratory Distress Syndrome, Newborn, Transient Tachypnea of the Newborn

Brief summary

The purpose of this observational study is to measure pulmonary function in term and preterm infants with and without pulmonary disease including respiratory distress syndrome, bronchopulmonary dysplasia, transient tachypnea of the newborn, meconium aspiration syndrome, and response to treatments given to newborn infants with lung diseases using a non-invasive airway oscillometry system.

Detailed description

TremoFlo™ N-100 (For Investigational Use Only) Airwave Oscillometry System™ (THORASYS Thoracic Medical Systems Inc. Montreal, Quebec, Canada) is a technology for measuring lung mechanics without patient effort. Pulmonary function testing using flow-volume and lung volumes is one of the most widely used tests to objectively measure lung function in adults. Such measurements are dependent on effort and coordination by the patient which is not possible for newborn infants. The minimum age for spirometry is typically 6 years to master the technique. Therefore, newborn infants usually require forced exhalation, flow interruption, and often sedation/anesthesia in order to obtain accurate pulmonary function measurements. Infant pulmonary function testing can be time-consuming and expensive to perform in newborn infants. This has limited the utilization of this potentially informative method of studying lung function. Measurements of lung function will be particularly informative during transition from having lungs filled with fluid during intra-uterine life to having lungs filled with air in extra-uterine life in preterm and term babies without lung disease, as well as in newborn infants with lung diseases including respiratory distress syndrome, bronchopulmonary dysplasia, transient tachypnea of the newborn, meconium aspiration syndrome, and after the effects of treatments given to newborn infants with lung diseases. The TremoFlo device uses the forced oscillation technique during spontaneous infant breathing and notably does not require any sedation to perform. The forced oscillation technique measures lung function by superimposing a gentle multi-frequency airwave onto the infant's respiratory airflow while the infant breathes spontaneously. Only a short period of breathing is required to obtain a reliable measurement of airway resistance and reactance. Oscillometry has been successfully utilized to quantify lung function in asthmatic children and adults with chronic obstructive pulmonary disease, but never previously in infants. This proposal brings this non-invasive technique of measuring lung function to the neonatal population to identify changes in respiratory mechanics between term and pre-term gestations and quantify fluctuations in infant lung function in response to disease progression and therapeutic intervention. The ease of oscillometry that only requires tidal breathing eliminates the need for patient cooperation and maneuvers that previously excluded lung function testing in the neonatal intensive care unit. This proposal will evaluate the feasibility and clinical value of oscillometry in newborns, both to detect changes in premature compared to full-term gestations as well as disease cohorts by introducing functional measures of lung function to bedside care.

Interventions

This is a non-invasive device will measure lung function in spontaneously breathing infants. Infants will have a cushioned mask placed on his/her face and the device will take measurements as the infant breathes normally.

Sponsors

University of Alabama at Birmingham
Lead SponsorOTHER
National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

This will be a single center prospective observational study with pre-specified Aims and Hypotheses

Eligibility

Sex/Gender
ALL
Age
1 Days to 2 Years
Healthy volunteers
Yes

Inclusion criteria

* Infants with gestational age at least 22 weeks at birth * Infants off ventilator/continuous positive airway pressure ≥ 12 hours * Infants whose parents/legal guardians have provided consent

Exclusion criteria

* Infants with major malformation * Infants with a neuromuscular condition that affects respiration * Infants with terminal illness * Infants with a decision made to withhold or limit support

Design outcomes

Primary

MeasureTime frameDescription
Area Under the Reactance Curve (AXR)40 weeks' postmenstrual age or discharge until 2 yearsAXR as the measure of overall measure of reactance of the respiratory system quantified by oscillometry and measured in cmH2O/L

Secondary

MeasureTime frameDescription
R7-2040 weeks' postmenstrual age or discharge until 2 yearsDifference between resistance at 7 Hz and 20 Hz in the respiratory system quantified by oscillometry and measured in cmH2O·s/L
R740 weeks' postmenstrual age or discharge until 2 yearsResistance at 7 Hz in the respiratory system quantified by oscillometry and measured in cmH2O·s/L
X740 weeks' postmenstrual age or discharge until 2 yearsReactance at 7 Hz in the respiratory system quantified by oscillometry and measured in cmH2O·s/L
Longer-term Pulmonary OutcomesUp to 2 yearsSevere morbidity: respiratory support including or CPAP or ventilation or tracheostomy; moderate morbidity: supplemental oxygen; treatment with daily pulmonary medications; ≥2 rehospitalizations for respiratory illness; ≥3 episodes of wheeze ≥2 weeks apart; mild morbidity: treatment with intermittent pulmonary medications; ≥2 episodes of wheeze ≥2 weeks apart; ≥2 medical visits for respiratory illness ≥2 weeks apart; 1 rehospitalization for respiratory illness)

Countries

United States

Contacts

STUDY_DIRECTORNamasivayam Ambalavanan, MD

University of Alabama at Birmingham

Baseline characteristics

Characteristic
Age, Categorical
<=18 years
600 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
6 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
218 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Gestational Age38 weeks
STANDARD_DEVIATION 1
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
5 Participants
Race (NIH/OMB)
Black or African American
255 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
133 Participants
Sex: Female, Male
Female
121 Participants
Sex: Female, Male
Male
65 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 1330 / 2280 / 940 / 145
other
Total, other adverse events
0 / 1330 / 2280 / 940 / 145
serious
Total, serious adverse events
0 / 1330 / 2280 / 940 / 145

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026